Format

Send to

Choose Destination
BMC Med Genet. 2014 Nov 30;15:127. doi: 10.1186/s12881-014-0127-0.

Expanded spectrum of exon 33 and 34 mutations in SRCAP and follow-up in patients with Floating-Harbor syndrome.

Author information

1
Institut für Vegetative Anatomie, Charité - Universitätsmedizin Berlin, Berlin, Germany. wenke.seifert@charite.de.
2
Institut für Humangenetik, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany. meinecke@uke.uni-hamburg.de.
3
Institut für Medizinische Genetik, Universität Rostock, Rostock, Germany. gkrueger@med.uni-rostock.de.
4
Genetikum Stuttgart, Stuttgart, Germany. rossier@genetikum.de.
5
Praxis für Humangenetik Cottbus, Cottbus, Germany. w.heinritz@humangenetik-cottbus.de.
6
Endokrinologikum Hamburg, Hamburg, Germany. achim.wuesthof@endokrinilogicum.de.
7
Institut für Medizinische Genetik und Humangenetik, Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Germany. denise.horn@charite.de.

Abstract

BACKGROUND:

Floating-Harbor syndrome is a rare autosomal dominant short stature syndrome with retarded speech development, intellectual disability and dysmorphic facial features. Recently dominant mutations almost exclusively located in exon 34 of the Snf2-related CREBBP activator protein gene were identified to cause FHS.

METHODS:

Here we report the genetic analysis of 5 patients fulfilling the diagnostic criteria of FHS obtained by Sanger sequencing. All of them presented with short stature, speech delay as well as psychomotor delay and typical facial dysmorphism. Three patients showed a good response to growth hormone treatment.

RESULTS:

Two patients demonstrate novel, heterozygous de novo frameshift mutations in exon 34 (c.7396delA and c.7218dupT) leading to premature stop mutations in SRCAP (p.Val2466Tyrfs*9 and p.Gln2407Serfs*36, respectively). In two further patients we found already known SRCAP mutations in exon 34, c.7330C > T and c.7303C > T, respectively, which also lead to premature stop codons: p.Arg2444* and p.Arg2435*. In one patient, we identified a novel de novo stop mutation in exon 33 (c.6985C > T, p.Arg2329*) demonstrating that not all FHS cases are caused by mutations in exon 34 of SRCAP.

CONCLUSIONS:

Our data confirm a mutational hot spot in the final exon of SRCAP in the majority of FHS patients but also show that exon 33 of this gene can be affected.

PMID:
25433523
PMCID:
PMC4412025
DOI:
10.1186/s12881-014-0127-0
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center